SCHEMBL23924054

SCHEMBL23924054

C[C@@H](CNc1ccc2[nH]cc(C(=O)O)c(=O)c2c1)NC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN22 Q9Y2R2 1/20 0.72
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 2/20 0.43
USP2 O75604 1/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
KDM4E B2RXH2 2/20 0.42
NR4A2 P43354 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ADRB2 P07550 1/20 0.42
RECQL P46063 1/20 0.42
HTT P42858 1/20 0.41
CFTR P13569 2/20 0.41
TRPV1 Q8NER1 1/20 0.40
POLB P06746 2/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923978 1.00 PTPN22 (0.72) PTPN22NPC1RAB9AHSD17B10USP2
SCHEMBL23947534 0.92 PTPN22 (0.61) PTPN22HSD17B10USP2TP53ALOX15
SCHEMBL23947942 0.89 PTPN22 (0.59) PTPN22NPC1RAB9AHSD17B10USP2
SCHEMBL23951220 0.89 PTPN22 (0.59) PTPN22NPC1RAB9AHSD17B10USP2
SCHEMBL23947588 0.89 PTPN22 (0.58) PTPN22HSD17B10USP2TP53ALOX15
SCHEMBL23923885 0.84 PTPN22 (1.00) PTPN22KDM4ENR4A2CFTR
SCHEMBL22885957 0.84 PTPN22 (1.00) PTPN22KDM4ENR4A2CFTR
SCHEMBL23947391 0.84 PTPN22 (1.00) PTPN22KDM4ENR4A2CFTR
SCHEMBL23947417 0.83 PTPN22 (0.80) PTPN22CFTRCTSLCTSBCTSS
SCHEMBL23948060 0.82 PTPN22 (0.79) PTPN22CFTRCTSLCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118290333-A Novel inhibitors of gonorrhoeae-specific tyrosine phosphatase (LYP) 普渡研究基金会 2024-07-05 CN disclosed
CN-115461056-B Inhibitors of Lebaba-specific tyrosine phosphatase (LYP) 普渡研究基金会 2024-04-16 CN disclosed
US-11629130-B2 Lymphoid-specific tyrosine phosphatase (LYP) inhibitors PURDUE RESEARCH FOUNDATION (US) 2023-04-18 US disclosed
EP-4135711-A1 NOVEL LYMPHOID-SPECIFIC TYROSINE PHOSPHATASE (LYP) INHIBITORS Purdue Research Foundation (US) 2023-02-22 EP disclosed
WO-2021211191-A1 NOVEL LYMPHOID-SPECIFIC TYROSINE PHOSPHATASE (LYP) INHIBITORS PURDUE RESEARCH FOUNDATION (US) 2021-10-21 WO disclosed
WO-2021211191-A1 NOVEL LYMPHOID-SPECIFIC TYROSINE PHOSPHATASE (LYP) INHIBITORS PURDUE RESEARCH FOUNDATION (US) 2021-10-21 WO disclosed
US-20210323926-A1 Novel Lymphoid-Specific Tyrosine Phosphatase (LYP) Inhibitors PURDUE RESEARCH FOUNDATION (US) 2021-10-21 US disclosed
US-20210323926-A1 Novel Lymphoid-Specific Tyrosine Phosphatase (LYP) Inhibitors PURDUE RESEARCH FOUNDATION (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11629130-B2 Lymphoid-specific tyrosine phosphatase (LYP) inhibitors PTPN22, PTPN1, PTPRCAP PTPN22 1/4885NPC1 4310/4885RAB9A 2365/4885
US-20210323926-A1 Novel Lymphoid-Specific Tyrosine Phosphatase (LYP) Inhibitors PTPN22, PTPN1, PTPRCAP PTPN22 1/4885NPC1 4352/4885RAB9A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.